Dr. Reddy’s avoids pitfalls of Ranbaxy, Wockhardt by cutting workers out of production Read more: Dr. Reddy’s avoids pitfalls of Ranbaxy, Wockhardt by cutting workers out of production

Posted on

New Drug Approvals

FDA pressure pushes Indian drugmakers to move away from relying predominantly on low-wage workers

The execs at Dr. Reddy’s Laboratories have taken notice as some of its competitors in India have run afoul of the FDA over loose manufacturing standards. The actions have meant banned plants and plummeting revenues for Ranbaxy Laboratories and Wockhardt. To avoid that fate, Dr. Reddy’s and some other Indian drugmakers have decided it is worth investing hundreds of millions of dollars for new plants and equipment in a country that has traditionally relied on cheap human labor.

Anji Reddy founded Dr Reddy’s in 1984 with Rs.25 lakh in initial capital. Photo: Mint

View original post

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s